Fibroxanthoma: UV Exposure, Diagnosis, and Treatment

Atypical fibroxanthoma (AFX) is a rare, low-grade skin tumor that typically appears as a painless, dome-shaped or ulcerated nodule on the sun-damaged skin of older adults, most often on the head and neck. Despite looking alarming under the microscope, where it shows bizarre, pleomorphic cells that can resemble aggressive cancers, AFX behaves in a surprisingly benign fashion when properly diagnosed and completely removed. The tension between its frightening histological appearance and its generally favorable prognosis is what makes AFX one of the more interesting and misunderstood tumors in dermatology.

What AFX Looks Like and Who Gets It

AFX usually shows up as a solitary, firm, pink-to-red nodule that grows slowly over weeks to months. It often ulcerates or bleeds, which is typically what prompts a visit to the doctor. The classic patient is an older man with a history of significant sun exposure, though women develop it too. The scalp, ears, nose, and cheeks are the most common locations, reflecting the role of cumulative ultraviolet damage in these chronically sun-exposed areas.¹ Most tumors are relatively small at diagnosis, often under two centimeters, and they tend to sit within the skin itself rather than extending deeply into underlying fat or muscle.

Because AFX can look like many other skin lesions, it rarely gets diagnosed on appearance alone. A red, bleeding nodule on an elderly person’s scalp could be a squamous cell carcinoma, a basal cell carcinoma, a melanoma, or even a benign cyst that has become irritated. Biopsy is almost always required. What the pathologist sees under the microscope is then the key to the diagnosis, though that process is itself a complicated one.

Ultraviolet Radiation and the Molecular Fingerprint

Chronic UV exposure is the dominant driver of AFX. This is true both clinically and at the molecular level. Studies examining the genetic mutations in AFX tumors found that the overwhelming majority carry the specific signature of UV-induced DNA damage: C-to-T transitions at sites in the genome where two pyrimidine bases sit next to each other. More than 70% of the mutations found in one genomic analysis fit this UV pattern.² Research on mutations in the p53 gene in AFX tumors provided the first direct evidence that UV radiation drives the development of this tumor, and it was also the first demonstration of solar UV-induced mutations in a human tumor arising from connective tissue rather than from the skin’s surface layer.³

Beyond p53, sequencing studies have identified recurrent mutations in several other genes, including NOTCH1, NOTCH2, FAT1, CDKN2A, and the TERT promoter. These mutations were found in more than half of the samples analyzed in one targeted sequencing study.⁴ The overall mutational burden is striking: AFX carries roughly 64 mutations per megabase of DNA, placing it among the most heavily mutated tumor types known.⁵ This very high mutation rate is typical of UV-driven cancers and has implications for potential immunotherapy approaches, as tumors with more mutations tend to produce more abnormal proteins that the immune system can recognize.

Immunosuppression as a Risk Factor

While sun damage is the primary risk factor, immunosuppression plays an important amplifying role. Organ transplant recipients on long-term anti-rejection medications develop AFX at younger ages than the general population and appear to have higher rates of recurrence and spread.⁶ Case reports describe cardiac transplant patients developing AFX of the ear after prolonged immunosuppressive therapy, often following a history of multiple other skin cancers.⁷ At least one transplant recipient developed three separate AFX tumors, a pattern essentially unheard of in people with normal immune systems.⁸

This matters because the reassuring prognosis typically quoted for AFX is largely based on data from people with healthy immune systems. Transplant recipients and others on immunosuppressive drugs should be monitored more carefully, and clinicians tend to treat these cases more aggressively as a result. Prior radiation therapy to the area is another recognized risk factor, though it accounts for a smaller fraction of cases.

How the Diagnosis Is Made

AFX is fundamentally a diagnosis of exclusion. When the pathologist looks at a biopsy and sees a dermal tumor packed with bizarre, pleomorphic spindle-shaped and epithelioid cells, the first job is to rule out things that look similar but behave very differently. The most common morphological pattern is a mixture of pleomorphic spindle and epithelioid cells, seen in roughly 60% of cases, with purely spindle-cell or predominantly epithelioid patterns making up the rest.⁹ Additional microscopic features can include hemorrhagic areas, granular cell changes, and myxoid changes, all of which can make the diagnosis harder.

Immunohistochemical staining, where the pathologist applies antibodies to the tissue to detect specific proteins, is essential. AFX does not have its own unique positive marker, so the approach involves a panel of stains to exclude other diagnoses. The marker CD10 is positive in the vast majority of AFX cases (roughly 27 out of 31 in one series) and much less commonly in squamous cell carcinoma or melanoma, making it one of the more useful tools in the diagnostic panel.¹⁰ The pathologist also checks for keratin markers to exclude squamous cell carcinoma, melanocytic markers to exclude melanoma, and various other stains to rule out leiomyosarcoma and other spindle-cell tumors.

Dermoscopy Clues Before the Biopsy

For clinicians trying to get a preliminary read before taking a biopsy, dermoscopy offers some useful clues. A multicenter study found that most AFX tumors show red structureless areas (about 83% of cases) and white structureless areas (about 70%), along with irregular linear blood vessels. A few features help distinguish AFX from other non-melanoma skin cancers: the presence of red and white structureless areas and white lines, combined with the absence of yellowish-white opaque scales and certain vessel patterns (hairpin vessels and branching arborizing vessels), favored a diagnosis of AFX.¹¹ These features are suggestive rather than definitive, but they can help a dermatologist decide where to direct the biopsy or raise clinical suspicion for what might otherwise look like a generic bleeding nodule.

The Critical Distinction From Pleomorphic Dermal Sarcoma

Perhaps the most important diagnostic question in AFX pathology is whether the tumor stays an AFX or crosses the line into pleomorphic dermal sarcoma (PDS), its more aggressive counterpart. The two tumors look very similar under the microscope and share many of the same genetic mutations.¹² What separates them is a set of adverse histological features. If the tumor invades deeply into the subcutaneous fat, shows tumor necrosis, or demonstrates invasion of blood vessels, lymphatic channels, or nerves, it is reclassified as pleomorphic dermal sarcoma.¹³

This distinction matters enormously for prognosis. AFX, when it meets strict diagnostic criteria and remains confined to the dermis without those adverse features, behaves in a benign fashion. PDS carries a meaningfully higher risk of recurrence and metastasis. The relationship between the two has led some researchers to view them as a spectrum rather than two completely separate diseases, with AFX sitting at the low-risk end. Historically, AFX was grouped with malignant fibrous histiocytoma (now reclassified as undifferentiated pleomorphic sarcoma), and the lack of clear boundaries between these entities created confusion about how aggressive AFX truly is.¹⁴ Modern classification, which insists on strict criteria separating AFX from PDS, has done a lot to clarify that true AFX carries a good prognosis.

Treatment Options

Surgery is the standard treatment, and the main question is how much tissue to take and how to verify that the margins are clear. The two primary surgical approaches are standard wide excision and Mohs micrographic surgery, where tissue is removed in thin layers and examined under the microscope in real time until no tumor remains at the edges. In a comparison of the two techniques, Mohs surgery produced zero recurrences over an average follow-up of about 30 months, while standard excision saw a 12% recurrence rate over roughly six years of follow-up. One of the patients treated with standard excision who recurred twice eventually developed metastasis to a parotid lymph node.¹⁵

Mohs surgery has the added advantage of conserving healthy tissue, which is particularly relevant given that most AFX tumors arise on the face and scalp where sparing normal skin matters for reconstruction. When surgery alone is not feasible, or when a patient is not a surgical candidate due to age or other medical conditions, radiation therapy can serve as an alternative or adjunct. Electronic brachytherapy, a form of localized radiation, has shown promising results in small series, particularly when the tumor is surgically debulked before radiation is applied. In one series of eight lesions, the recurrence rate was zero among tumors that were debulked first.¹⁶ A newer approach using high-dose-rate plesiotherapy with 3D-printed customized molds has shown good clinical and cosmetic results, and may be especially useful for tumors in anatomically awkward locations like the ear or nose where achieving clean surgical margins is difficult.¹⁷

Prognosis and Follow-Up

The overall outlook for properly treated AFX is quite good. A meta-analysis of individual patient data found a one-year recurrence risk of about 3% and a five-year risk of roughly 7%. The median time to recurrence was 13 months, and the risk of recurrence beyond two years was very low, under 1%.¹⁸ A large single-institution series reported an even lower recurrence rate of about 1.3%.¹⁹

Certain factors do increase recurrence risk. The same meta-analysis found that patients older than 74 at the time of diagnosis had a substantially higher risk of local recurrence, and men were at higher risk than women.²⁰ The fact that most recurrences happen within the first one to two years informs the surveillance schedule: close follow-up during that window is most important, with visits gradually spacing out afterward.

The role of imaging and sentinel lymph node biopsy in AFX management remains unclear. Expert opinion holds that these tools are unlikely to be helpful in most straightforward AFX cases, given the tumor’s low metastatic potential.²¹ Imaging may be reserved for cases that recur, that have worrisome histological features bordering on PDS, or that arise in immunosuppressed patients.

When AFX Appears in Unexpected Patients

The textbook AFX patient is an elderly man with a bald, sun-damaged scalp, but the tumor does occasionally break from this pattern. Case reports have documented AFX arising in young women with no identifiable risk factors, presenting as a rapidly growing nodule on the nose.²² Other reports describe giant or recurrent AFX arising on non-chronically sun-damaged skin in younger patients, with molecular analysis revealing TP53 mutations even in the absence of the typical UV damage history.²³ These atypical presentations serve as reminders that a biopsy is warranted for any suspicious nodule, even when the patient does not fit the demographic profile.

AFX on non-sun-exposed skin raises questions about whether UV-independent pathways can drive the tumor in some cases. The finding of p53 mutations in tumors arising on relatively protected skin suggests that while UV light accounts for the large majority of cases, it may not be the only way the critical genes get knocked out. The numbers here are too small to draw firm conclusions, but clinicians should not dismiss the possibility of AFX simply because the lesion is not on the face or scalp.

Immunotherapy and the Future of Advanced Disease

True AFX almost never metastasizes, so systemic therapy is seldom needed. When a tumor originally diagnosed as AFX does spread, it has often been reclassified as PDS or undifferentiated pleomorphic sarcoma after a closer look at the pathology. For those rare aggressive cases, the very high mutational burden of these tumors has drawn interest in immune checkpoint inhibitors. Experimental data and clinical case reports involving PD-1/PD-L1-blocking antibodies in patients with unresectable or metastatic PDS suggest that immunotherapy could serve as a first-line treatment in advanced stages of this disease spectrum.²⁴

Individual case reports have described meaningful responses to anti-PD-1 agents in patients with metastatic cutaneous sarcomas that had high levels of PD-L1 expression or high tumor mutational burden, though severe immune-related toxicity has also been documented.²⁵ The evidence base here is still limited to case reports and small series, not randomized trials, so immunotherapy for this tumor family remains investigational. But the biological rationale is strong: tumors this heavily mutated tend to produce many abnormal proteins that the immune system can target, which is exactly the scenario where checkpoint inhibitors perform best in other cancer types. Given how rarely AFX and PDS reach a stage where systemic therapy is even considered, large trials will be difficult to organize, and treatment decisions in advanced cases will likely continue to rely on biomarker-guided individualized approaches for the foreseeable future.

The Evolving Molecular Landscape

Research into the genetics of AFX is still relatively young but has already reshaped how pathologists think about the tumor. Initial studies using a variety of genomic approaches have confirmed a core set of recurrently mutated genes in AFX: TP53, NOTCH1/2, FAT1, CDKN2A, and the TERT promoter.²⁶ What makes this interesting, and somewhat frustrating, is that these same mutations appear in PDS at similar frequencies.²⁷ So far, no single genetic marker reliably distinguishes AFX from PDS. The boundary between the two still rests on histological features like depth of invasion and the presence or absence of necrosis and vascular invasion, rather than on any molecular test.

This overlap has fueled the ongoing debate about whether AFX and PDS are truly different diseases or different stages along a single continuum. Some researchers suspect that AFX may, in rare cases, progress to PDS over time, much as a low-grade glioma can evolve into a high-grade one in the brain. But proving this progression in skin tumors that are usually removed early is extremely difficult. For now, the classification system works well enough in practice: tumors that stay confined to the dermis without worrisome features do well, and those that push deeper or show aggressive histological signs do not. Whether future molecular markers will add another layer to this distinction, perhaps identifying the small subset of “AFX” tumors that are truly at risk of behaving aggressively, remains an open and actively investigated question.